Prourocare Medical (PUMD) vs. T2 Biosystems (TTOO) Head to Head Contrast
Prourocare Medical (OTCMKTS:PUMD) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.
Earnings and Valuation
This table compares Prourocare Medical and T2 Biosystems’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|T2 Biosystems||$4.66 million||41.30||-$62.42 million||N/A||N/A|
Volatility and Risk
Prourocare Medical has a beta of 8.37, meaning that its stock price is 737% more volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500.
Institutional and Insider Ownership
56.3% of T2 Biosystems shares are owned by institutional investors. 29.3% of Prourocare Medical shares are owned by insiders. Comparatively, 31.5% of T2 Biosystems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of recent recommendations and price targets for Prourocare Medical and T2 Biosystems, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
T2 Biosystems has a consensus price target of $10.07, indicating a potential upside of 130.36%. Given T2 Biosystems’ higher probable upside, analysts plainly believe T2 Biosystems is more favorable than Prourocare Medical.
This table compares Prourocare Medical and T2 Biosystems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
T2 Biosystems beats Prourocare Medical on 5 of the 9 factors compared between the two stocks.
About Prourocare Medical
ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Artann Laboratories Inc. for its ProUroScan System. ProUroCare Medical Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.
About T2 Biosystems
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications, as well as T2Candida panel for the detection of candida species in human whole blood specimens. In addition, it is developing T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; T2Lyme for the detection of various strains of Lyme disease-causing bacteria; and T2Plex, an integrated instrument for hemostasis applications. The company has collaboration agreement with Canon U.S. Life Sciences, Inc. to develop a novel diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC for the direct detection diagnostic test panel that adds additional bacteria species to the existing T2Bacteria product candidate and testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Prourocare Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prourocare Medical and related companies with MarketBeat.com's FREE daily email newsletter.